Your browser doesn't support javascript.
loading
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
Shikata, Kenichi; Ito, Sadayoshi; Kashihara, Naoki; Nangaku, Masaomi; Wada, Takashi; Okuda, Yasuyuki; Sawanobori, Tomoko; Sugimoto, Kotaro.
Afiliação
  • Shikata K; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Ito S; Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
  • Kashihara N; Katta General Hospital, Shiroishi, Japan.
  • Nangaku M; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
  • Wada T; Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Okuda Y; Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
  • Sawanobori T; Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Sugimoto K; Clinical Development Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
J Diabetes Investig ; 13(7): 1190-1202, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35199478

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article